David Altshuler - May 17, 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
May 17, 2021
Transactions value $
-$17,093
Form type
4
Date filed
5/19/2021, 04:02 PM
Next filing
Nov 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$1.72K -8 -0.02% $215.31 33.7K May 17, 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$12.1K -56 -0.17% $216.31 33.6K May 17, 2021 Direct F1, F3, F4
transaction VRTX Common Stock Sale -$3.26K -15 -0.04% $217.13 33.6K May 17, 2021 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $215.31 (range $214.83 to $215.77).
F3 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $216.31 (range $215.83 to $216.80).
F5 Open market sales reported on this line occurred at a weighted average price of $217.13 (range $216.86 to $217.50).